Leerink Partners Remains Bullish on Amicus Therapeutics (FOLD) Following Announced Scioderm Acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- UBS Reiterates Buy Rating on Snowflake Inc. (SNOW)
Cowen Raises Price Target on Amicus Therapeutics (FOLD) Following Announced Deal for Scioderm
September 1, 2015 7:10 AM EDTCowen reiterated an Outperform rating on Amicus Therapeutics (NASDAQ: FOLD), and raised the price target to $27.00 (from $19.00), following the announced cash/stock deal for Scioderm. Scioderms Zorblisa is in a Ph3 trial for the rare skin disease Epidermolysis Bullosa (EB) with FDA Breakthrough... More
Notable Mergers and Acquisitions 8/31: (FOLD) (ITT) (KANG) (NX)
August 31, 2015 9:51 AM EDT* Amicus Therapeutics (NASDAQ: FOLD) and Scioderm, Inc. a privately-held biopharmaceutical company focused on developing innovative therapies for treating diseases with high unmet need, have signed a definitive agreement under which Amicus will acquire 100% of the capital stock of Scioderm, Inc.
Transaction highlights
Excellent strategic fit with Amicus' patient-centric vision to develop and commercialize advanced therapies for devastating rare and orphan diseasesLeverages Scioderm development team's EB expertise with Amicus' global clinical infrastructure to advance Zorblisa toward regulatory approvals and Amicus' commercial, patient advocacy and medical affairs infrastructure to support a successful global... MoreAmicus Therapeutics (FOLD) to Acquire Scioderm in ~$950M Deal
August 31, 2015 6:29 AM EDTAmicus Therapeutics (NASDAQ: FOLD) and Scioderm, Inc. a privately-held biopharmaceutical company focused on developing innovative therapies for treating diseases with high unmet need, have signed a definitive agreement under which Amicus will acquire 100% of the capital stock of Scioderm, Inc.
Transaction highlights
Excellent strategic fit with Amicus' patient-centric vision to develop and commercialize advanced therapies for devastating rare and orphan diseasesLeverages Scioderm development team's EB expertise with Amicus' global clinical infrastructure to advance Zorblisa toward regulatory approvals and Amicus' commercial, patient advocacy and medical affairs infrastructure to support a successful global... More